Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: Real-world UK experience

European Journal of Ophthalmology

Volumn 27, Issue 3, 2017, Pages 357-362

  El Ghrably, Ibraheem ^a   Steel, David H W ^b,c   Habib, Maged ^b   Vaideanu Collins, Daniela ^a   Manvikar, Sridhar ^a   Hillier, Roxane J ^d  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b SUNDERLAND EYE INFIRMARY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Diabetic macular edema; Fluocinolone acetonide; Iluvien

Indexed keywords

FLUOCINOLONE ACETONIDE; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL MACULAR THICKNESS; DEVICE MIGRATION; DEVICE SAFETY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; FEMALE; HUMAN; INTRAOCULAR PRESSURE; INTRAVITREAL IMPLANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHACOEMULSIFICATION; PRIORITY JOURNAL; TREATMENT OUTCOME; VERY ELDERLY; VITRECTOMY; CLINICAL TRIAL; COMPLICATION; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; UNITED KINGDOM; VISUAL ACUITY;

ADULT; AGED; AGED, 80 AND OVER; DIABETIC RETINOPATHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; UNITED KINGDOM; VISUAL ACUITY;

EID: 85019370066     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000929     Document Type: Article

References (25)

1. Yau JW, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35(3):556-564.
2. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102(1): 7-16.
3. Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol. 1984;28(Suppl):452-461.
4. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98(5)(Suppl):766-785.
5. Ferris F. Early photocoagulation in patients with either type I or type II diabetes. Trans Am Ophthalmol Soc. 1996;94:505-537.
6. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077.e35.
7. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
8. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11): 2247-2254.
9. Gross JG, Glassman AR, Jampol LM, et al; Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA. 2015;314(20):2137-2146.
10. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4(6):151-169.
11. Brown DM, Nguyen QD, Marcus DM, et al; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10): 2013-2022.
12. Boyer DS, Nguyen QD, Brown DM, et al. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials. Ophthalmology. 2015;122(12):2504-2513.e1.
13. Wells JA, Glassman AR, Ayala AR, et al; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13): 1193-1203.
14. Campochiaro PA, Brown DM, Pearson A, et al; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125-2132.
15. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626-635.e2.
16. Boyer DS, Yoon YH, Belfort R Jr, et al; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904-1914.
17. Danis RP, Sadda S, Li XY, Cui H, Hashad Y, Whitcup SM. Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials. Br J Ophthalmol. 2016;100(6):796-801.
18. Alimera Sciences Limited. Summary of product characteristics for ILUVIEN 190 micrograms intravitreal implant in applicator. www.medicines.org.uk/emc/medicine/27636. Accessed September 5, 2016.
19. NICE. NICE technology appraisals [TA301]. Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). 2013.
20. Bertelmann T, Schulze S. Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant. Ophthalmol Ther. 2015;4(1):51-58.
21. Schmit-Eilenberger VK. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series. Clin Ophthalmol. 2015;9:801-811.
22. Elaraoud I, Andreatta W, Kidess A, et al. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting. BMC Ophthalmol. 2016;16:3.
23. Sivaprasad S, Oyetunde S. Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion. Clin Ophthalmol. 2016;10:939-946.
24. El-Ghrably IA, Saad A, Dinah C. A Novel Technique for Repositioning of a Migrated ILUVIEN(®) (Fluocinolone Acetonide) Implant into the Anterior Chamber. Ophthalmol Ther. 2015;4(2): 129-133.
25. Parrish RK II, Campochiaro PA, Pearson PA, Green K, Traverso CE; FAME Study Group. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials. Ophthalmic Surg Lasers Imaging Retina. 2016;47(5): 426-435.